Dexamethasone treatment of VCaP prostate cells
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51872
下载链接
链接失效反馈官方服务：
资源简介：
The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide. We identified glucocorticoid receptor (GR) activity as modulator of enzalutamite sensitivity in the VCaP prostate cancer cell line. The GR agonist dexamethasone was sufficient to confer enzalutamide resistance whereas a GR antagonist restored sensitivity. These expression profiling data demonstrate that GR transcriptional activity overlaps with that of AR in the VCAP model. VCAP cells growing in complete media were treated with the indicated drugs in biological triplicates for 24 hours prior to harvest.
创建时间：
2018-08-13
